Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval

Core Viewpoint - Kura Oncology Inc. is expected to see significant stock growth, with Barclays raising its price target to $28 from $11, driven by the approval of ziftomenib [1] Group 1: Company Overview - Kura Oncology is a clinical-stage biopharmaceutical company focused on developing cancer treatments [4] Group 2: Product Approval - The US FDA granted full approval to KOMZIFTI (ziftomenib) for treating adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible NPM1 mutation [2] - KOMZIFTI is the first and only once-daily oral menin inhibitor approved for AML, which affects approximately 30% of AML cases [2] Group 3: Clinical Trial Data - The approval of KOMZIFTI is supported by data from the pivotal KOMET-001 trial involving 112 R/R NPM1-mutated AML patients, showing a combined complete remission rate of 21.4% [3] - The safety profile of KOMZIFTI is favorable, with no Boxed Warning for QTc prolongation or Torsades de Pointes, allowing for easier co-administration with other medications [3]